Plant ID: NPO4307
Plant Latin Name: Canarium album
Taxonomy Genus: Canarium
Taxonomy Family: Burseraceae
NCBI TaxonomyDB:
300208
Plant-of-the-World-Online:
127264-1
Antirheumatic
Cambodia; Vietnam; China; Thailand; Japan; Taiwan
GPR35; | |
RECQL; TDP1; HPGD; AKR1B1; HSD17B2; APEX1; POLB; | |
TEK; INSR; MET; SRC; MAPK1; EGFR; NUAK1; KDR; IGF1R; CSNK2A1; | |
CA12; CA9; CA7; | |
NR1H4; | |
KDM4E; | |
TYR; | |
AHR; | |
FUT7; | |
SLC22A6; SLCO1B3; | |
SMAD3; LMNA; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 1.288E-09 | 4.517E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.106E-08 | 2.183E-05 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 4.357E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.717E-07 | 7.477E-05 | AKR1B1, APEX1, CA9, CSNK2A1, CYP1A2, EGFR, HPGD, INSR, SRC, TEK |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.929E-07 | 8.235E-05 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, NR1H4, SMAD3, SRC, TEK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 4.544E-07 | 1.596E-04 | EGFR, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.483E-07 | 2.172E-04 | CYP1A1, CYP1A2, CYP1B1 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.463E-07 | 2.676E-04 | CA9, EGFR, HPGD, SLC22A6, SLCO1B3, TEK |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.276E-06 | 3.518E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.443E-06 | 5.846E-04 | CA12, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.190E-06 | 7.015E-04 | APEX1, POLB |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.270E-06 | 7.120E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.529E-06 | 7.533E-04 | EGFR, IGF1R, INSR, KDR, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 6.069E-06 | 1.191E-03 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MAPK1, MET, NUAK1, RECQL, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.088E-06 | 1.354E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.580E-06 | 1.435E-03 | EGFR, INSR, MET, SRC, TEK |
CC | GO:0016020; membrane | GO:0005901; caveola | 8.050E-06 | 1.486E-03 | INSR, MAPK1, SLC22A6, SRC |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 1.678E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.558E-06 | 1.678E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 2.974E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.909E-05 | 2.974E-03 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.366E-05 | 3.458E-03 | CYP1A2, EGFR, MAPK1 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.607E-05 | 3.785E-03 | AHR, CSNK2A1, KDR |
BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 2.776E-05 | 3.926E-03 | EGFR, KDR, MAPK1, TEK |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.179E-05 | 4.348E-03 | CYP1A1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 3.444E-05 | 4.490E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.588E-05 | 4.568E-03 | APEX1, CYP1A1, CYP1B1, EGFR, MAPK1, SRC |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.735E-05 | 4.674E-03 | CA12, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.790E-05 | 4.691E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, EGFR, HSPA1A |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.763E-05 | 5.576E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.763E-05 | 5.576E-03 | CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 4.763E-05 | 5.576E-03 | CYP1A1, CYP1A2, KDM4E |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 5.542E-05 | 6.285E-03 | EGFR, INSR, SMAD3 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 6.660E-05 | 7.109E-03 | CYP1A2, CYP3A4 |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 6.660E-05 | 7.109E-03 | EGFR, POLB |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.859E-05 | 7.286E-03 | CA12, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 7.497E-05 | 7.849E-03 | EGFR, INSR, KDR, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 8.870E-05 | 9.154E-03 | CYP1A1, CYP1A2 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 9.742E-05 | 9.913E-03 | CYP1A1, LMNA, SMAD3, SRC, TEK |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.168E-13 | 7.338E-11 | SMAD3, CSNK2A1, SRC, INSR, MAPK1, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.476E-09 | 1.758E-07 | SRC, INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.439E-08 | 1.155E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.135E-07 | 3.224E-06 | INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.223E-08 | 1.854E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.779E-07 | 6.577E-06 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.290E-06 | 2.035E-05 | SRC, KDR, MAPK1, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.757E-06 | 2.494E-05 | INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.253E-06 | 2.035E-05 | SRC, KDR, MAPK1, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.432E-07 | 1.913E-05 | INSR, MAPK1, TEK, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.335E-06 | 3.947E-05 | SMAD3, INSR, MAPK1, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 7.025E-06 | 7.673E-05 | MAPK1, MET, EGFR, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.850E-06 | 7.962E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.629E-05 | 2.333E-04 | SRC, MAPK1, EGFR, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.247E-05 | 1.181E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.648E-04 | 1.232E-03 | SRC, KDR, MAPK1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.991E-04 | 1.285E-03 | MAPK1, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.901E-04 | 1.285E-03 | INSR, HSPA1A, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.640E-05 | 3.876E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.000E-05 | 3.945E-04 | SRC, MAPK1, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.083E-04 | 1.286E-03 | SMAD3, MAPK1, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.973E-04 | 2.736E-03 | SMAD3, MAPK1, MET, EGFR, IGF1R |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.991E-04 | 1.285E-03 | CYP1A2, CYP1A1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.178E-04 | 1.289E-03 | MAPK1, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.276E-04 | 1.293E-03 | SRC, MET, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 4.705E-04 | 2.463E-03 | SRC, MAPK1, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.029E-04 | 2.463E-03 | MAPK1, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 5.367E-04 | 2.540E-03 | SRC, MAPK1, EGFR |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.586E-04 | 1.413E-03 | SLCO1B3, NR1H4, CYP3A4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 4.866E-04 | 2.463E-03 | SRC, MAPK1, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.736E-03 | 6.848E-03 | CYP1B1, MAPK1, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.102E-03 | 7.514E-03 | SMAD3, SRC, MAPK1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 2.021E-03 | 7.514E-03 | INSR, MAPK1, EGFR |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.942E-03 | 7.453E-03 | SMAD3, MAPK1, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.283E-06 | 3.947E-05 | CA12, CA7, CA9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.630E-03 | 9.109E-03 | SRC, MAPK1, EGFR |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05020 | Prion diseases | 1.707E-03 | 6.848E-03 | MAPK1, HSPA1A |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 2.117E-03 | 7.514E-03 | INSR, MAPK1 |
Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 1.016E-03 | 4.508E-03 | MAPK1, EGFR |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.173E-03 | 5.046E-03 | CYP1A2, CYP3A4 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.518E-03 | 6.341E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; CA9; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; MAPK1; EGFR; SRC; CA9; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
C00-D49: Neoplasms | AML | NA | KDR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; CA9; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
NA: NA | HIV infections | NA | AHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; MAPK1; EGFR; SRC; CA9; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |